Printer Friendly

Profectus begins Phase I trial of rVSV-vectored HIV-1 vaccine.

M2 PHARMA-January 5, 2012-Profectus begins Phase I trial of rVSV-vectored HIV-1 vaccine(C)2012 M2 COMMUNICATIONS

5 January 2012 - Profectus BioSciences Inc, a US-based vaccine developer, said that, as of 27 December 2011, 20 volunteers have been immunised as part of its Phase I trial designed to asses the safety and immunogenicity of a recombinant vesicular stomatitis virus (rVSV)-vectored HIV vaccine.

The new rVSV vector, expressing the HIV-1 gag protein, is being assessed in a study partly-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study is being conducted by the NIAID-funded HIV Vaccine Trials Network (HVTN) under a protocol designated HVTN 090.

The Phase I, placebo-controlled, dose-escalation study will enrol 60 HIV-uninfected adults and will evaluate the safety and immunogenicity of increasing doses of the rVSV HIV-1 gag vaccine.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 5, 2012
Previous Article:Prana gets FDA nod to initiate study of PBT2 in Huntington's disease.
Next Article:Basilea to seek European approval for antibiotic ceftobiprole in H2 2012.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters